ALKS · Alkermes plc. · Executive Compensation
$46.85
+1.40 (+3.08%)
At close · Nov 18
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.87B
Shares
168.04M
Volume · Nov 18
1.41M
Avg daily vol (3M)
1.89M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chief Executive Officer and Chairman | $7,915,081 |
| Blair C. Jackson | Executive Vice President, Chief Operating Officer; Former Interim Principal Financial Officer | $4,030,905 |
| Joshua Reed | Senior Vice President, Chief Financial Officer | $3,797,074 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $3,617,908 |
| David J. Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $3,470,083 |
| Todd Nichols | Senior Vice President, Chief Commercial Officer | $2,790,694 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chief Executive Officer and Chairman | $10,131,193 |
| Blair C. Jackson | Executive Vice President, Chief Operating Officer and Chief Risk Officer; Interim Principal Financial Officer | $4,891,034 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $4,343,991 |
| David J. Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $4,115,355 |
| Todd Nichols | Senior Vice President, Chief Commercial Officer | $3,319,071 |
| Iain M. Brown | Senior Vice President, Chief Financial Officer | $2,819,570 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chief Executive Officer and Chairman | $9,442,066 |
| Blair C. Jackson | Executive Vice President, Chief Operating Officer and Chief Risk Officer; Interim Principal Financial Officer | $4,561,915 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $4,226,388 |
| David J. Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $4,135,728 |
| Iain M. Brown | Senior Vice President, Chief Financial Officer | $3,209,824 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chief Executive Officer and Chairman | $10,314,172 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $4,546,920 |
| Blair C. Jackson | Executive Vice President, Chief Operating Officer and Chief Risk Officer; Interim Principal Financial Officer | $4,470,120 |
| David J. Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $4,291,952 |
| Iain M. Brown | Senior Vice President, Chief Financial Officer | $3,312,694 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chairman and Chief Executive Officer | $8,846,588 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $4,727,478 |
| Blair C. Jackson | Executive Vice President, Chief Operating Officer and Chief Risk Officer | $3,769,824 |
| David J. Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $3,117,266 |
| Iain M. Brown | Senior Vice President, Chief Financial Officer | $2,886,669 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chairman and Chief Executive Officer | $8,041,702 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $3,957,135 |
| David J. Gaffin | Senior Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $2,890,136 |
| Mr. James M. Frates | Former Senior Vice President, Chief Financial Officer | $2,372,772 |
| Michael J. Landine | Senior Vice President, Corporate Development and Chief Risk Officer | $2,310,421 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chairman and Chief Executive Officer | $14,637,147 |
| James A. Robinson | Former President and Chief Operating Officer | $4,155,073 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $3,656,337 |
| David J. Gaffin | Senior Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $3,540,962 |
| Mr. James M. Frates | Former Senior Vice President, Chief Financial Officer | $3,082,241 |
| Michael J. Landine | Senior Vice President, Corporate Development and Chief Risk Officer | $2,996,741 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chairman and Chief Executive Officer | $17,055,802 |
| James A. Robinson | Former President and Chief Operating Officer | $6,727,868 |
| Craig Hopkinson | Executive Vice President, Research and Development and Chief Medical Officer | $3,791,198 |
| Mr. James M. Frates | Former Senior Vice President, Chief Financial Officer | $3,616,930 |
| David J. Gaffin | Senior Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | $3,596,198 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Richard F. Pops | Chairman and Chief Executive Officer | $9,380,493 |
| Mr. James M. Frates | Senior Vice President, Chief Financial Officer | $2,828,545 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anne C. Whitaker | Director | Appointed | 2026-09-16 |
| Blair C. Jackson | Chief Executive Officer | Appointed | 2026-02-25 |
| Richard F. Pops | Chief Executive Officer | Retired | 2026-02-25 |
| Joshua Reed | Senior Vice President, Chief Financial Officer | Appointed | 2025-09-12 |
| Christopher I. Wright, M.D., Ph.D. | director | Appointed | 2024-05-31 |
| Nancy L. Snyderman, M.D. | director | Appointed | 2024-05-31 |
| Frank Anders Wilson | director |
Already on the board
Since at least 2019: re-election or new board role
|
2024-05-31 |
| Richard F. Pops | director |
Already on the board
Since at least 2011: re-election or new board role
|
2024-05-31 |
| Nancy S. Lurker | director | Appointed | 2024-05-31 |
| Brian P. McKeon | director |
Already on the board
Since at least 2020: re-election or new board role
|
2024-05-31 |
| Cato T. Laurencin, M.D., Ph.D. | director | Appointed | 2024-05-31 |
| Richard B. Gaynor, M.D. | director | Appointed | 2024-05-31 |
| David A. Daglio, Jr. | director |
Already on the board
Since at least 2021: re-election or new board role
|
2024-05-31 |
| Shane M. Cooke | director |
Already on the board
Since at least 2018: re-election or new board role
|
2024-05-31 |
| Emily Peterson Alva | director |
Already on the board
Since at least 2021: re-election or new board role
|
2024-05-31 |
| Nancy S. Lurker | director | Appointed | 2024-03-07 |
| Samuel J. Parisi | interim principal accounting officer | Appointed | 2024-02-05 |
| Blair C. Jackson | interim principal financial officer | Appointed | 2024-02-05 |
| Frank Anders Wilson | Lead Independent Director | Appointed | 2023-12-08 |
| Nancy J. Wysenski | board of directors | Retired | 2023-12-08 |
| Christopher I. Wright, M.D., Ph.D. | Class II director | Appointed | 2022-07-07 |
| Brian P. McKeon | Class II director |
Already on the board
Since at least 2020: re-election or new board role
|
2022-07-07 |
| Cato T. Laurencin, M.D., Ph.D. | Class II director | Appointed | 2022-07-07 |
| Emily Peterson Alva | Class II director | Appointed | 2022-07-07 |
| Christopher I. Wright | Class II member of the Board | Appointed | 2022-05-27 |
Leadership
- Blair C. Jackson CEO, CFO, COO
- Mr. Richard F. Pops CEO
- Iain M. Brown CFO, Chief Accounting Officer
- Blair Jackson COO
- James A. Robinson COO
- Samuel J. Parisi Chief Accounting Officer
- Andy Wilson Board Member
- Anne C. Whitaker Board Member
- Brian McKeon Board Member
- Brian P. McKeon Board Member
- Cato T. Laurencin Board Member
- Cato T. Laurencin, M.D., Ph.D. Board Member
- Christopher I. Wright Board Member
- Christopher I. Wright, M.D., Ph.D. Board Member
- David A. Daglio, Jr. Board Member
- David Daglio Board Member
- Dr. Cato T. Laurencin Board Member
- Nancy L. Snyderman Board Member
- Nancy L. Snyderman, M.D. Board Member
- Nancy S. Lurker Board Member
- Richard B. Gaynor Board Member
- Richard B. Gaynor, M.D. Board Member
- Richard F. Pops Board Member
- Shane M. Cooke Board Member
Key facts
CIK
1520262
CUSIP
G01767105
13F (30d)
424 filings
387 filers
Visit website
Investor relations